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Around 430 000 new cases of breast caner (BC) 
occur each year in Europe and an estimated of 180 510 
in USA [1, 2]. Breast cancer is the most commonly 
diagnosed cancer after non-melanoma skin cancer, 
and it is the second most common cause of cancer 
mortality after lung cancer. The lifetime prevalence of 
breast cancer is about 13% in women, according to 
the National Cancer Institute data, and it is extremely 
rare but highly lethal in men [3]. This statistics is ap-
proximately common for all industrialized countries. 
Hereditary breast cancer is associated with a poorer 
survival than sporadic counterpart, which may have 
consequences for treatment [4]. Breast carcinomas 
are routinely graded according to Scarff — Bloom — 
Richardson modified by Elston and Ellis [5], based on 
the assessment of tubule formation, nuclear pleomor-
phism and mitotic counts. 
There are several frequent histological types of 
breast carcinomas: ductal carcinoma in situ, lobular 
carcinoma in situ, in one hand, and rarely, medullary 
carcinoma, mucinous carcinoma and tubular carci-
noma. Ductal carcinoma in situ (DCIS) is a noninvasive 
neoplasm originating in the duct, which in some cases 
can become invasive. Thanks to the increased acces-
sibility of screening mammography technique, DCIS 
is diagnosed more frequently and accounts for up to 
30% of all malignant breast lesions [3]. In contrast, 
lobular carcinoma in situ is defined as a proliferation of 
gene rally small and often loosely cohesive cells origi-
nating in the terminal duct-lobular unit, with or without 
pagetoid involvement of terminal ducts [6].
To a large extent histology determines prognosis, 
regarding mucinous, medullary and tubular carci-
nomas as more favorable types. Medullary breast 
carcinoma (MBC) is characterized by the high graded 
structure and heavy lymphocytic infiltration, and usu-
ally have favorable prognosis. The aim of this review 
was to illuminate unique biological features and outline 
theoretical basis to further investigations of medullary 
breast carcinoma. 
LYMPHOCYTIC INFILTRATION IS A UNIQUE 
FEATURE OF MBC
Medullary breast carcinoma is well circumscribed 
and soft in consistency with a homogeneous grey and 
moist cut surface, although haemorrhage and necrosis 
were present in some cases. Microscopically, tumors 
consisted of large tumor cells, showed marked mitotic 
activity but no striking nuclear pleomorphism [7]. The 
characteristic feature of MBC is a dense lymphocytic 
infiltration of the tumor stroma. It is a morphologically 
and biologically distinct subtype of invasive carcinoma 
characterized by the presence of solid sheets of large 
and pleomorphic cells with indistinct cell borders that 
lead to a syncytial appearance [8], constituting ap-
proximately 3–6% of all invasive breast cancers [9]. 
At mammograms, MBC appeared as round or oval 
non-calcified masses with varying degrees of marginal 
lobulation [10]. Medullary carcinoma has a second 
type termed atypical. Atypical medullary carcinoma is 
diagnosed either when more than 25% of the tumor is 
not of the classical medullary type, or when the lym-
phoid infiltration is moderate, or when circumscription 
is incomplete [11]. Despite the cytological anaplastic 
features and high mitotic rate, the prognosis for MBC 
is surprisingly better than for other types of infiltrating 
ductal carcinomas, with 84% 10-year survival rate, 
which is significantly higher than for patients with non-
MBC (63%) [12, 13]. The positive correlation between 
the intensity of lymphoid infiltration and patient’s 
survival suggests that the immune system may be 
involved in restraining the spread of this type of breast 
cancer. In several studies was demonstrated that the 
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lymphoid infiltration consists of T, B, and plasma cells, 
with predominance of cytotoxic CD8+T cells as well as 
large numbers of CD4+T, B, and plasma cells [8]. In 
other investigation lymphocytic mononuclear tumor 
inflammatory cells in 16 cases of medullary carcinoma 
were mostly CD45RO+/CD3+ T cells while natural killer 
cells (CD57+) and  histocytes (MAC387+) were virtually 
absent [14]. 
The absence of neutrophils indicates that the 
tumor-infiltrating leukocytes in MBC accumulate in 
response to specific stimuli and not to nonspecific 
inflammatory response caused by tumor necrosis or 
bacterial agents [13]. Several hypotheses were pro-
posed to explain the biological basis for the favorable 
prognosis of patients with MBC, including enhanced 
tumor cell apoptosis [15, 16], elevated levels of me-
tastasis-inhibiting factors [15], increased levels of the 
adhesion molecule-1 (ICAM-1) expression [17].
Interestingly, that some other cancers also possess 
prominent lymphoplasmacytic infiltrates associated 
with a favorable prognosis, suggesting that effective 
anti-cancer responses may develop spontaneously. 
However, a large body of evidence suggests that in 
case of non-MBC breast carcinomas the high level of 
tumor associated macrophages correlates with poor 
prognosis [18]. The tumor-promoting activities of tu-
mor associated macrophages (TAM) may be the result 
of their ability to express numerous tumor-promoting 
factors, such as growth factors, angiogenic mediators, 
extracellular matrix degrading enzymes and inflamma-
tory cytokines [19–21]. The inflammatory cytokines 
promote leukocyte infiltration to sites of inflammation 
and their expansion is inducible, primarily, by pro-
inflammatory cytokines. It was also suggested that TAM 
might contribute to tumor progression by the release 
of reactive oxygen intermediates [19, 20]. These pro-
ducts may induce mutagenic changes that could result 
in increased DNA damage and generation of diversity 
within the tumor [19, 21]. Therefore, tumor infiltrating B 
lymphocyte could promote the major tumor suppressive 
effect in MBC, but in case of other breast carcinomas 
the efficacy of infiltration is questionable.
The risk factors, such as lymph node status, tumor 
size, steroid receptor status, and menopausal status, 
which are known to be of major prognostic importance 
for all other types of breast cancer, have minimal pro-
gnostic value in case of MBC, indicating that MBC is 
a subtype with unique biological features.
It is important that lymphoplasmacytic infiltrates of 
the breast can be associated not only with MBC, but 
also appear as a consequence of blood cell diseases, 
such as extranodal lymphoma or/and extramedullary 
plasmacytoma (EP). EP is a malignant tumor composed 
entirely of plasma cells in the absence of bone marrow 
infiltration. Occurring in soft tissue, EP, frequently ap-
pears in upper respiratory tract, oral cavity and rare in 
the breast [22]. Extranodal non-Hodgkin’s lymphoma 
(NHL) localizes in the breast appears as a primary 
breast lymphoma [23]. Primary breast lymphoma 
(PBL) is a rare presentation of extranodal lymphoma. 
The most common histology for PBL is the diffuse large 
B-cell type [24–26] and less frequent is extranodal 
marginal zone B-cell lymphoma (MALT) [25]. Some 
authors have speculated that extramedullary plasma-
cytoma may represent a form of extranodal marginal 
zone B-cell lymphoma (MALT-type lymphoma) with 
extreme plasmacytic differentiation [27].
In the case of localization in breast these diseases 
may be readily mistaken for medullary breast carci-
noma not only clinically, but also on cytological exa-
mination. Since microscopic and histological analysis 
often shows similar morphology of different types of 
breast tumors, investigation of gene expression profile 
could help to discriminate between these tumors. Im-
munohistochemically, the extramedullary plasmacy-
tomas cells are focally positive for vimentin, diffusely 
strongly positive for immunoglobulin IgA and kappa 
light chains, and negative for IgG, IgM, lambda light 
chains, leukocyte common antigen, CD20, cytokera-
tin, S100, HMB45, and smooth muscle antigen [22]. 
In contrast, MBC is dominantly IgG positive [13], and 
expresses all the glandular type cytokeratins, including 
CK19 [28]. Immunohistochemical analysis of primary 
breast diffuse large B-cell lymphoma showed positive 
staining for melanoma associated antigen (mutated) 
1 (MUM1), Bcl-2 (in one-half cases) and negative for 
CD10 [29]. Thus, in spite of similar morphology of MBC 
and PBL or EP, these types of tumors could be distin-
guished based on analysis of gene expression.
ANTIGENIC REPERTOIRE OF MBC
Continuing progress in the development of an-
tigen specific breast cancer vaccines depends on 
the identification of appropriate target antigens, the 
establishment of effective immunization strategies, 
and the ability to circumvent immune escape mecha-
nisms. Methods, such as T cell epitope cloning and 
serological expression cloning (SEREX), have led to 
the identification of a number of antigens expressed 
in breast cancer [30]. At first, target antigens must 
be presented as processed peptides, bound to MHC 
class I and class II molecules. Recognition of these 
MHC-peptide complexes on the surface of antigen 
presenting cells by antigen-specific T lymphocytes, 
together with additional co-stimulation, leads to the 
proliferation of antigen-specific CD8+ and CD4+ T cells 
that have lytic and immunostimulatory functions [30]. 
In some solid tumors immunocompetent B cells are 
known to contribute to spontaneous tumor regression 
[31]. Both naturally occurring and vaccine-induced 
antibody responses to breast cancer antigens could 
be associated in some cases with improved survival 
[32]. One of the first target molecules to be examined 
in the context of a breast cancer vaccine is carcino-
embrionic antigen (CEA), a differentiation antigen of 
the gut, expressed exclusively in normal colonic epi-
thelium and approximately in 50% of breast cancers 
[33]. With regard to clinical trials, Morse et al. [34] 
have observed objective responses in patients with 
metastatic disease, including breast cancer, following 
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immunization with dendritic cells pulsed with human 
leukocyte antigen (HLA)-A2 restricted CEA peptide. 
Recently, a new differentiation antigen of the breast, 
NY-BR-1, was identified by SEREX analysis, and it was 
found to be expressed exclusively in normal testis and 
breast, as well as in 80% of breast cancers [35]. Their 
significance in relation to breast cancer vaccines is 
under investigation [30]. Additionally, MBC and atypi-
cal MBC differ in expression profile of some antigens, 
such as human leukocyte antigen (HLA)-DR and β2 
microglobulin [36].
Since the high density of B lymphocytes infiltra-
tion in MBC may reflect an ongoing immune response 
against transformed cells, it is of great interest to 
identify the B-cells targets as important implications 
for detection and treatment, not only for the MBC, but 
all other types of breast cancer. The novel techniques 
for antigen searching in MBC are predominantly based 
on the analysis of libraries containing variable regions 
of immunoglobulin genes of tumor infiltrating B cells. In 
one of this investigation Ig-rearranged V region Vh-Jh, 
Vκ-Jκ, and Vλ-Jλ genes, amplified by RT-PCR of the 
infiltrating B cells, were cloned, sequenced, and sub-
jected to a comparative DNA analysis. A combinatorial 
single-chain Fν κ (scFνκ) minilibrary from selected VH 
and Vκ region genes was generated and tested there-
after for the breast tumor cell-binding capacity. The 
specific binding was confirmed by FACS analysis with 
primary breast carcinoma cells and ELISA. Thin layer 
chromatography and dot-blot experiments showed 
this target antigen to be a ganglioside D3 (GD3) [37]. 
Gangliosides have been extensively investigated for 
their structural and functional properties [38], as well 
as their role in tumor cell transformation and potential 
capacity as suitable tumor targets for diagnostics 
or therapeutics. In addition to the well-defined GD2 
overexpression in neuroblastomas and melanomas 
[39, 40], GD3 may be the useful marker MBC. 
In other research, in order to determine the role of 
the antibody response produced by the local infiltrating 
cells B lymphoplasmacytic cell infiltrates were analyzed 
in MBC [13]. IgG antibody phage display libraries were 
generated from MBC-infiltrating lymphoplasmacytic 
cells of two patients, and MBC-reactive monoclonal 
antibodies were retrieved by selection on fresh-frozen 
MBC tissue sections. Mass spectrometry analysis 
revealed that the antigen targeted by the domi nant 
clones in the oligoclonal B lymphoplasmacytic re-
sponse in both patients was not a cancer-specific 
antigen but the cytoskeletal actin protein.
MBC exhibits an increased rate of apoptosis, and 
apoptotic MBC cells were shown to expose actin on the 
cell surface, permitting its recognition by the humoral 
immune system. Further, actin fragments, similar to 
those observed after cleavage with the apoptotic pro-
tease granzyme B, were observed in MBC tissue [13]. 
In general, these results demonstrate the use of 
clonal analysis and antibody phage display technolo gy 
in dissection of a local immune response and identi-
fication of tumor-associated antigens as targets for 
cancer immunotherapy. Further elucidation of the 
immune response in MBC and the biological features 
intrinsic to these cancer cells should give clues to the 
favorable prognosis of MBC.
MOLECULAR BIOLOGY OF MBC
The fact that the tumor cells harbor a multitude of 
genetic defects suggests that survival or response to 
cancer therapy is not associated with a single genetic 
defect but may result from a combination of various 
defects. The molecular mechanism behind the fre-
quently detected instability of the genome of breast 
cancer cells is poorly understood, but some studies 
have shown the association with mutations in the p53, 
BRCA1 or BRCA2 genes [41]. BRCA1 and BRCA2 mu-
tations were found in over 90% of all hereditary breast 
cancer cases but in contrast to BRCA1, a BRCA2 
mutation also confers an increased risk for breast 
cancer in male [42]. p53 and BRCA1/BRCA2 are 
tumor-suppressor genes involved in apoptosis [43], 
transcriptional regulation [44], DNA double-strand 
repair [45], cell-cycle arrest [46], etc. The new roles 
for BRCA1 in heterochromatin formation in chromo-
some X and ubiquitination have been identified recently 
[47]. BRCA1 associated tumors are usually estrogen 
receptor (ER) negative (between 63 and 90%) [48, 
49], while the majority of BRCA2 associated cancers 
are ER-positive [50].
In addition, it was suggested that ER expression 
in BRCA1 associated tumors is related to the age of 
patients [48, 50]. The most common tumor suppressor 
gene mutations detected in about ¼ of breast tumors 
are in the p53 gene. Mutations in p53 gene are found 
in 20–40% of invasive breast cancers and its overex-
pression detected in 37–77% of BRCA1 associated 
tumors [51]. The direct functional link between p53 
and BRCA1 was initially suggested by the observation 
that loss of p53 can partially rescue embryonic lethali-
ty in BRCA1 knockout mice [52]. Breast carcinomas 
with p53 mutations are consistently associated with 
negative assays for ER and progesterone receptor 
(PR) [53], and variably associated with amplification 
of some oncogenes, such as HER-2/neu, c-myc and 
ras. Overexpression of HER2 protein is found extremely 
rare in breast carcinomas with BRCA1 mutations. How-
ever, HER2/neu overexpression is found in 25–30% 
cases of breast cancers [52].
The alterations in these genes are more common 
for MBC. The present data indicate that p53 alteration 
is an important factor in typical MBC but probably 
combines with other specific genetic defects that 
could explain the paradoxically increased sensitivity of 
MBC to treatment. In the typical MBC the frequency 
of p53 mutations ranges from 50 to 100% [51]. The 
percentage of HER-2/neu expression in MBC ranged 
from less than 10% to 33%, depending on the sample 
size of MC cases, detection method used, and the 
criteria for defining MBC [54].
It was shown that MBC also have been associa-
ted with early-onset hereditary breast carcinomas 
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due to the BRCA1 gene mutations [47]. Medullary 
carcinomas, which harbor p53 and Chk2 mutations 
(human homolog of Rad53), have the high frequency 
of methylation dependent transcriptional silencing of 
BRCA1 [55].
The MBC shows enhanced tumor cells apopto-
sis, elevated levels of metastasis-inhibiting factors, 
elevated levels of adhesion molecule ICAM-1 and 
the effective host immune response [56]. The genes 
most frequently involved in breast carcinogenesis 
(MYC, CCND1, EGFR and CCNE) very rarely ampli-
fied in MBC [57]. Recently 265 genes that involved in 
the architecture and remodeling of cytoskeleton were 
identified as underexpressed in basal MBCs by mic-
roarray assay. Among them there are actins (ACTG2, 
ACTA2), α-actinin (ACTN1), myosin light chain (MYL9), 
ß-tropomyosin (TPM2), and several regulators or as-
sociated proteins [9]. 
The recent investigations have identified a number 
of genes, including several members of the GAGE and 
insulin growth factor binding protein (IGFBP) gene 
families, Vav1 (guanine nucleotide exchange factor 
(GEF)), monoglyceride lipase and NADP+ dependent 
malic enzyme, which exhibited altered expression 
in MBC versus ductal breast cancer [9]. By immu-
nohistochemical analysis it was established that the 
expression of monoglyceride lipase was restricted to 
ductal breast cancer, and was found in 77% of these 
tumors, while Vav1 was restricted to MBC and was 
present in 60% of tumors [9]. The MBC differs from 
ductal carcinoma by high expression level of human 
lymphocytic antigen HLA-DR, one of the major histo-
compatibility complex class (MHC II) antigens, which 
normally present in all nucleated cells [30]. Recently, 
it has been reported that the loss of secreted Frizzled-
related protein 1 (SFRP 1) gene, a putative tumor 
suppressor protein involved in the WNT [58] pathway, 
was observed in most invasive ductal carcinomas but 
not shown in MBC [53]. The absence of apoptosis 
inhibitor protein Bcl-2 expression in MBC has been 
described also [59] 
The detection of the alterations in these genes 
would allow to understand the nature of MBC more 
clearly, and to create new gene therapy strategies in 
the nearest future.
FURTHER PERSPECTIVES OF BREAST 
CANCER TREATMENT
Systemic adjuvant chemo-, endocrine -and/or ra-
diotherapy are the first line treatment in breast cancer 
after surgery of the primary tumor, directed to eradi-
cate disseminated tumor cells as a potential cause of 
metastatic growth. Unfortunately, the heterogeneity of 
solid tumors including different cell cycle phases and 
resistance mechanisms create a problem for all kinds 
of therapy, and limit the chance of complete elimination 
of all residual tumor cells.
The implementation of screening programs for the 
early detection of breast cancer and the development 
of the chemotherapy, radiotherapy, and anti-estrogen 
therapies has improved the survival of the breast 
cancer patients. The development of target selective 
therapy is the next step in breast cancer treatment. 
So, the identification of proteins and/or antigens, 
which expression is elevated in breast cancer tissues 
compared with normal breast tissue, is an important 
step in the development of breast cancer therapies 
[60]. The tumor-associated antigens are the keys 
for the development of anti-cancer vaccines and 
monoclonal antibodies, which could make cancer 
therapy more harmless and efficient. Monoclonal 
antibody Herceptin, generated against ERBB2 recep-
tor (her2/neu), successfully used in breast cancer 
treatment [61]. Dense lymphocytic infiltration of MBC 
enables assumption of existence of one or few highly 
expressed autoantigens, which could make basis for 
further investigations in immunotherapy of breast 
carcinomas. Further investigation of ganglioside D3 
and actin overexpression in MBC could extend the 
antigen repertoire, and allow developing active or pas-
sive immunotherapy for MBC treatment.  All aforesaid 
treatment strategies have their pluses and minuses, 
but restrictions of classical cancer treatment will drive 
researchers to search for novel strategies for breast 
cancer treatment.
CONCLUSIONS
A relatively favorable prognosis for MBC corre-
lates with heavy lymphocytic infiltration of this tumor. 
Absence of IgA antibody that predominates in normal 
breast tissue, and generally presence of IgG is a sign 
of antigen-specific immune response in MBC. It has 
been hypothesized that infiltrating plasma cells react 
with an antigen and directly or indirectly involved in 
control of tumor progression. Several investigations 
of MBC antigenic repertoire found a number of highly 
expressed tumor specific antigens such as β-actin, 
ganglioside D3, HLA-DR and β2-microglobulin. These 
antigens could be considered as targets for cancer 
immunotherapy as well as for generation therapeutic 
monoclonal antibodies. 
Further search for antigens, present in MBC, could 
bring the light on nature of favorable prognosis not only 
in MBC, but in the other types of breast carcinomas 
as well. The understanding of the role of the infiltrating 
elements in MBC would help to create efficient thera-
peutic strategies for breast cancer treatment.
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МЕДУЛЛЯРНАЯ КАРЦИНОМА МОЛОЧНОЙ ЖЕЛЕЗЫ
Рак молочной железы является наиболее распространенным онкологическим заболеванием среди женщин. Медуллярная 
карцинома молочной железы (МКМЖ) представляет собой вид инвазивного рака протоков молочной железы, который часто 
имеет благоприятный прогноз, характеризуется высоким уровнем дифференцировки, высоким митотический индексом и 
выраженной лимфоидной инфильтрацией. Именно это свойство делает МКМЖ привлекательной мишенью для детального 
изучения при разработке новых иммунотерапевтических подходов к лечению рака. В данном обзоре мы суммировали данные 
о морфологии, антигенном спектре и особенностях молекулярной биологии МКМЖ. Основная цель обзора — освещение 
уникальных биологических особенностей и определение теоретической основы для дальнейших исследований МКМЖ.
Ключевые слова: медуллярная карцинома молочной железы, лимфоидная инфильтрация, иммуноглобулин, антиген.
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